Free Trial

Foyston Gordon & Payne Inc Reduces Position in Sanofi (NASDAQ:SNY)

Sanofi logo with Medical background

Foyston Gordon & Payne Inc lessened its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 80.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,784 shares of the company's stock after selling 24,228 shares during the period. Foyston Gordon & Payne Inc's holdings in Sanofi were worth $333,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. MidWestOne Financial Group Inc. grew its position in shares of Sanofi by 5.4% during the 3rd quarter. MidWestOne Financial Group Inc. now owns 25,156 shares of the company's stock worth $1,450,000 after buying an additional 1,296 shares in the last quarter. Abel Hall LLC grew its holdings in Sanofi by 5.2% during the 3rd quarter. Abel Hall LLC now owns 10,796 shares of the company's stock worth $622,000 after acquiring an additional 534 shares in the last quarter. Barclays PLC increased its position in Sanofi by 107.5% during the 3rd quarter. Barclays PLC now owns 639,772 shares of the company's stock valued at $36,869,000 after purchasing an additional 331,445 shares during the period. Drucker Wealth 3.0 LLC increased its position in Sanofi by 3.9% during the 3rd quarter. Drucker Wealth 3.0 LLC now owns 15,254 shares of the company's stock valued at $879,000 after purchasing an additional 578 shares during the period. Finally, Orion Portfolio Solutions LLC raised its holdings in shares of Sanofi by 6.1% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 64,286 shares of the company's stock valued at $3,705,000 after purchasing an additional 3,707 shares in the last quarter. Hedge funds and other institutional investors own 10.04% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on SNY shares. StockNews.com lowered shares of Sanofi from a "buy" rating to a "hold" rating in a report on Friday. Citigroup upgraded Sanofi to a "strong-buy" rating in a report on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $57.50.

View Our Latest Research Report on Sanofi

Sanofi Stock Down 0.7 %

NASDAQ:SNY traded down $0.35 during midday trading on Tuesday, reaching $48.08. 1,793,862 shares of the stock traded hands, compared to its average volume of 2,056,386. The stock has a market capitalization of $122.02 billion, a PE ratio of 24.71, a price-to-earnings-growth ratio of 1.23 and a beta of 0.58. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The business has a 50-day moving average of $51.71 and a two-hundred day moving average of $52.12.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping analysts' consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm had revenue of $13.44 billion during the quarter, compared to analysts' expectations of $16.59 billion. During the same quarter last year, the firm earned $2.55 EPS. The business's quarterly revenue was up 12.3% on a year-over-year basis. On average, equities analysts forecast that Sanofi will post 4.27 earnings per share for the current fiscal year.

Sanofi Company Profile

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Further Reading

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

→ 3 CENT Crypto to Explode December 16th? (From True Market Insiders) (Ad)

Should you invest $1,000 in Sanofi right now?

Before you consider Sanofi, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.

While Sanofi currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Analysts Predict Big Gains for These 3 Cybersecurity Leaders
This Investment Strategy Has the Highest Payout Potential
Watch These 4 Growth Sectors Thrive in 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines